Epic Sciences, a San Diego, CA-based developer of liquid biopsy tests to predict drug response in cancer patients, completed a $40m Series D financing.
The round was led by Hermed Capital, with participation from Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures.
Epic plans to use the funds to accelerate clinical studies for oncology tests in its pipeline as well as enhance its proprietary No Cell Left Behind technology to include characterization of rare leukocyte cell populations with digital imaging and big data analytics. These enhancements are designed to drive transformative insights into the cellular drivers of response or resistance to key drug classes such as immuno-oncology drugs.
Led by Murali Prahalad, Ph.D., president and CEO, Epic is developing a portfolio of blood-based tests that predict drug response in cancer. The company recently partnered with Genomic Health to commercialize the OncotypeDx® AR-V7 Nucleus Detect™ test to leverage Genomic Health’s commercial channel and enterprise systems.